Most health plans, including Medicare, provide continuous glucose monitor coverage for people with diabetes who either use insulin or have a documented history of dangerous low blood sugar. Private insurers largely follow that same framework but add their own prior authorization rules, so two patients with identical records can see different outcomes depending on the plan. Getting approved comes down to meeting the clinical criteria, assembling the right paperwork before you submit, and knowing how to push back if the first answer is no.
Who Qualifies for Coverage
Medicare’s Local Coverage Determination sets the baseline that most commercial insurers model their own policies on. You need a diabetes diagnosis, a prescription from your treating provider, training on how to use the device, and use that is consistent with the monitor’s FDA clearance.1Centers for Medicare & Medicaid Services. LCD – Glucose Monitors (L33822)
On top of those basics, you must meet at least one of two clinical thresholds. The first is simple: you are treated with insulin. The second covers patients with problematic hypoglycemia, documented as either recurrent level 2 events (glucose below 54 mg/dL) that persist despite medication adjustments, or at least one level 3 event where your mental or physical state was impaired enough that someone else had to help you.1Centers for Medicare & Medicaid Services. LCD – Glucose Monitors (L33822)
Your doctor also has to see you in person or by telehealth within six months before ordering the device, and follow-up visits every six months are required to keep coverage active.2Centers for Medicare & Medicaid Services. Glucose Monitoring Supplies
Commercial insurers want to see the same building blocks but often draw the lines differently. Some will approve patients with Type 2 diabetes who are not on intensive insulin therapy if they can show recurrent hypoglycemia or poor glycemic control despite medication changes.3UnitedHealthcare. Continuous Glucose Monitoring and Insulin Delivery for Managing Diabetes A patient denied by one carrier might be approved by another with the same chart. If you’re shopping plans during open enrollment, pulling up each one’s CGM policy is worth the time.
Medicaid rules vary significantly by state. Some cover both Type 1 and Type 2 patients broadly, others restrict access by age or complication history.
Non-Insulin Users Under Medicare
Medicare has expanded eligibility beyond insulin users, but only within limits. If you manage your diabetes with oral medications, you can qualify only if you have documented problematic hypoglycemia meeting the level 2 or level 3 criteria above. Taking oral diabetes medication alone isn’t enough. Medicare has made the point explicit that insulin doesn’t come in pill form, so patients on oral drugs only are not “insulin-treated” for coverage purposes.1Centers for Medicare & Medicaid Services. LCD – Glucose Monitors (L33822)
Gestational Diabetes
Coverage during pregnancy is growing but inconsistent. Some major insurers will authorize a monitor for the duration of pregnancy for patients with gestational, Type 1, or Type 2 diabetes, but prior authorization is almost always required, and decisions tend to be individualized because the clinical evidence for CGM use in gestational diabetes is still considered limited compared to Type 1. If you want a monitor during pregnancy, ask your OB or endocrinologist to submit the prior authorization early. Approvals can take weeks.
What You’ll Pay
Under Medicare, CGMs fall under Part B as durable medical equipment. The Part B annual deductible for 2026 is $283.4Centers for Medicare & Medicaid Services. 2026 Medicare Parts A and B Premiums and Deductibles After the deductible, you pay 20% of the Medicare-approved amount if your supplier accepts assignment.5Medicare.gov. Continuous Glucose Monitors A Medigap plan may absorb some or all of that coinsurance.
With private insurance, one detail that catches people off guard is how the plan classifies the device. Some plans treat the monitor as a pharmacy benefit, which usually means lower copays and faster fulfillment through a retail or mail-order pharmacy. Others treat it as durable medical equipment, which can mean higher coinsurance and a different supplier network. Ask your plan which category applies before you start the authorization. It changes both your cost and where the order gets filled.
CGMs and their supplies are eligible expenses under an HSA, FSA, or HRA, because the IRS treats blood sugar monitoring as a cost of diagnosing and treating disease.6Internal Revenue Service. Publication 502 (2025) – Medical and Dental Expenses That covers copays, coinsurance, and deductible payments as well as the device itself. If you itemize, CGM costs exceeding 7.5% of adjusted gross income can be deducted on Schedule A, though pre-tax HSA or FSA dollars usually produce a bigger benefit than the itemized deduction.
Documentation to Assemble Before You Ask
Most denials come from missing paperwork, not genuine ineligibility. Pulling the full package together before anything gets submitted avoids the back-and-forth that stretches approval by weeks.
- A prescription that specifies the device, the sensors, and any transmitter or receiver. If you don’t have a compatible smartphone, the prescription should include a standalone reader.
- A visit note from a face-to-face or telehealth appointment within the last six months, confirming your diagnosis and that the coverage criteria are met.
- Blood glucose logs covering roughly 30 to 60 days of readings, which can come from a fingerstick meter download or a handwritten log.
- Proper ICD-10 diagnosis coding, which your physician will select based on your situation.7Centers for Medicare & Medicaid Services. Billing and Coding – Implantable Continuous Glucose Monitors (I-CGM)
- If you’re qualifying based on hypoglycemia rather than insulin use, records detailing each episode: dates, glucose readings, whether another person had to help, and any ER visits or hospitalizations.
Many insurers also ask for a letter of medical necessity from your doctor. The strongest letters explain why your current monitoring is failing and how continuous data will change your outcomes. Boilerplate letters that could apply to any diabetic patient are the most common reason a request gets bounced back for more information.
How the Request Moves
Once documentation is assembled, the route depends on how your plan classifies the device. Pharmacy-benefit orders go to a pharmacy that stocks CGM supplies, which tends to be faster. DME orders go through a specialized supplier that handles insurance verification, billing, and shipping. A good supplier will give you an estimated out-of-pocket cost before you finalize the order.
For Medicare prior authorizations, the standard decision window is seven calendar days, and expedited requests must be decided within two business days.8Noridian Medicare. New Timeframe for Prior Authorization Decisions Private insurers set their own timelines, but federal rules require a decision within 30 days for non-urgent pre-service requests, or 72 hours if your doctor flags clinical urgency.
Once approved, a CGM prior authorization is typically good for 12 months.9UnitedHealthcare. Changes to Continuous Glucose Monitor Prior Authorization Requirement Put the expiration date on your calendar. If you let it lapse, you’ll have to start over, including a fresh physician visit. Most suppliers coordinate recurring sensor shipments during the authorization period so you don’t run out between orders.
If You’re Denied
Read the denial letter carefully before doing anything else. The insurer has to state the specific reason for the rejection, and that reason usually points directly at what needs fixing: an overlooked visit note, a weak letter of medical necessity, or a coding error.
Internal Appeal
The first step is an internal appeal with your insurer. For a pre-service denial, the plan has to decide within 30 days, or 72 hours for urgent situations. Your physician can request a peer-to-peer review, which is a phone call between your doctor and a physician reviewer at the insurance company. These calls reverse a lot of denials, because your doctor can explain the clinical picture in a way the paperwork alone did not.
External Review
If the internal appeal fails, federal law gives you the right to an independent external review. You have to file within four months of the final internal denial. An independent review organization — not the insurer — evaluates whether the denial was correct, and must issue a decision within 45 days for standard cases or 72 hours when your health is at immediate risk.10eCFR. 45 CFR 147.136 – Internal Claims and Appeals and External Review Processes That decision binds the insurer. Supplementing the record at this stage is difficult, which is why thorough documentation at the start matters.
If You Don’t Qualify
Two FDA-cleared over-the-counter monitors are available without a prescription, aimed at different users than prescription CGMs and not covered by insurance. Dexcom Stelo is cleared for adults 18 and older who do not use insulin, is not intended for people prone to severe hypoglycemia, and does not provide high or low glucose alerts. Abbott Lingo is cleared as a general health and wellness tool for adults and is not cleared for people with diabetes, with a reading range limited to 55 to 200 mg/dL and no out-of-range alerts.
Neither replaces a prescription CGM for managing diabetes, because they lack the alert features that make prescription monitors a safety tool for insulin users and anyone at risk of hypoglycemia. If you have a diabetes diagnosis and purchase an OTC CGM, the cost may still qualify as an eligible HSA or FSA expense; IRS Notice 2024-75 identified certain CGMs for diabetes patients as preventive care, which can make them eligible even under a limited-purpose FSA, though LPFSA rules vary by employer.